Info

Novacea, Inc. (Novacea) is a biopharmaceutical company focused on in-licensing, developing and commercializing therapies for the treatment of cancer. The Company’s product portfolio features two clinical-stage oncology product candidates with worldwide rights, Asentar and AQ4N, each of which is a potential treatment for certain types of cancer. In May 2007, the Company signed an exclusive worldwide license agreement with Schering Corporation (Schering) for the development and commercialization of Asentar. The Company continues to be primarily involved in performing research and development activities, hiring personnel, licensing new products, and raising capital to support and expand these activities.(Source: 10-K)